CN Bio’s LiverChip Helps Battle Hepatitis B

A tool for testing treatments

Next Steps

Hughes says CN Bio plans to use LiverChip to expand into drug development. Despite the technology’s strengths, it can’t model side effects such as birth defects or cancer, says David Jacobson-Kram, a former Food and Drug Administration toxicologist who consults for drugmakers. The Defense Advanced Research Projects Agency has pledged $63 million to Harvard and MIT to develop a chip that provides a fuller picture by linking facsimiles of 10 different organs.

    Before it's here, it's on the Bloomberg Terminal.
    LEARN MORE